# EDGAR Filing Document

**Accession Number:** 0001684693
**File Stem:** 0001178913-25-002176
**Filing Date:** 2025-6
**Character Count:** 9324
**Document Hash:** e3e4b4df5028b95a425315cf34da6b7e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-002176.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001178913-25-002176

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sol-Gel Technologies Ltd.
- **CENTRAL INDEX KEY:** 0001684693
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90328
- **FILM NUMBER:** 251043465

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 GOLDA MEIR ST.
- **STREET 2:** WEIZMANN SCIENCE PARK
- **CITY:** NESS ZIONA
- **NON US STATE TERRITORY:** L3
- **PROVINCE COUNTRY:** L3
- **ZIP:** 7403648
- **BUSINESS PHONE:** 97289313433

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 GOLDA MEIR ST.
- **STREET 2:** WEIZMANN SCIENCE PARK
- **CITY:** NESS ZIONA
- **NON US STATE TERRITORY:** L3
- **PROVINCE COUNTRY:** L3
- **ZIP:** 7403648
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arkin Moshe
- **CENTRAL INDEX KEY:** 0001321178

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 6 HACHOSHLIM ST.
- **CITY:** HERZELIA
- **STATE:** L3
- **ZIP:** 4672406

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Sol-Gel Technologies Ltd**

*(Name of Issuer)*

**Ordinary Shares, par value NIS 1.0 per share**

*(Title of Class of Securities)*

**M8694L137**

*(CUSIP Number)*

**Perry Wildes, Adv.**<br>One Azrieli Center<br>Tel Aviv L3 6701101<br>972-3-607-4444

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/29/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **M8694L137** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Moshe Arkin** | Name of reporting person<br>**Moshe Arkin** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**143257.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1806856.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**143257.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1806856.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1950113.00** | Aggregate amount beneficially owned by each reporting person<br>**1950113.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**65.31%** | Percent of class represented by amount in Row (11)<br>**65.31%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b).

Row 13: Based on 2,785,787 Ordinary Shares outstanding on June 11, 2025, as provided by the Issuer.

| **CUSIP No.** | **M8694L137** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**M. Arkin Dermatology Ltd.** | Name of reporting person<br>**M. Arkin Dermatology Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1806856.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1806856.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1806856.00** | Aggregate amount beneficially owned by each reporting person<br>**1806856.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**60.52%** | Percent of class represented by amount in Row (11)<br>**60.52%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b).

Row 13: Based on 2,785,787 Ordinary Shares outstanding on June 11, 2025, as provided by the Issuer.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value NIS 1.0 per share

**(b) Name of Issuer:**
Sol-Gel Technologies Ltd

**(c) Address of Issuer's Principal Executive Offices:**
7 Golda Meir St., Weizmann Science Park, Ness Tziona, L3, 7403648

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of Schedule 13D is hereby amended and restated as follows: 

(a) and (b)

As of June 11, 2025, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares, which represented beneficial ownership of approximately 60.52% of the Company's outstanding Ordinary Shares. Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology.
 
As of June 11, 2025, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 143,257 Ordinary Shares, which represented beneficial ownership of approximately 5.14% of the Company's outstanding Ordinary Shares.  Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. 

In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 1,806,856 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 65.31% of the Company's outstanding Ordinary Shares.  Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology.

The total Ordinary Shares beneficially owned by Mr. Arkin as of June 11, 2025, is 1,950,112, which represented beneficial ownership of 65.31% of the Company's outstanding Ordinary Shares.

**(b)**
—

**(c)**
Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Moshe Arkin

**Signature:** /s/ Moshe Arkin

**Name/Title:** Moshe Arkin

**Date:** 06/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** M. Arkin Dermatology Ltd.

**Signature:** /s/ Moshe Arkin

**Name/Title:** Moshe Arkin, Director

**Date:** 06/12/2025